Bruker Corporation (BRKR)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $9.41B
Last updated: Nov 17, 2026 at 11:05 AM ET
Bruker Corporation (BRKR) Earnings: Report Dates and Results
Bruker (BRKR) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Bruker reported EPS of $0.56, above the $0.42 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BRKR has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 35.6% above the $0.59 reported for the quarter ended Dec 31, 2025.
BRKR Earnings Call
The latest BRKR earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, BRKR beat 31, missed 4 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $874.00M, up 1.6% from $860.50M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.56 | $0.42 | $0.39 - $0.45 | +33.33% | Beat | +24.4% | 12 | 1 up, 1 down | Nov 4, 2026 | $874.00M |
| Jun 30, 2026 | $0.49 | $0.38 | $0.36 - $0.40 | +28.95% | Beat | +53.1% | 12 | 1 up, 1 down | Aug 4, 2026 | $838.50M |
| Mar 31, 2026 | $0.31 | $0.23 | $0.21 - $0.25 | +34.78% | Beat | -34.0% | 13 | 1 up, 3 down | May 6, 2026 | $823.40M |
| Dec 31, 2025 | $0.59 | $0.65 | $0.62 - $0.78 | -9.23% | Miss | -22.4% | 14 | 1 up, 1 down | Feb 12, 2026 | $977.20M |
| Sep 30, 2025 | $0.45 | $0.32 | $0.30 - $0.34 | +40.63% | Beat | -25.0% | 12 | 2 up, 1 down | Nov 3, 2025 | $860.50M |
| Jun 30, 2025 | $0.32 | $0.42 | $0.34 - $0.49 | -23.81% | Miss | -38.5% | 13 | 2 up, 3 down | Aug 4, 2025 | $797.40M |
| Mar 31, 2025 | $0.47 | $0.44 | $0.37 - $0.50 | +6.82% | Beat | -11.3% | 13 | 4 up, 2 down | May 7, 2025 | $801.40M |
| Dec 31, 2024 | $0.76 | $0.74 | $0.71 - $0.76 | +2.70% | Beat | +8.6% | 14 | 2 up, 1 down | Feb 13, 2025 | $979.60M |
| Sep 30, 2024 | $0.60 | $0.60 | $0.52 - $0.64 | 0.00% | In line | -18.9% | 12 | 0 up, 0 down | Nov 5, 2024 | $864.40M |
| Jun 30, 2024 | $0.52 | $0.51 | $0.46 - $0.56 | +1.96% | Beat | +4.0% | 10 | 2 up, 0 down | Aug 6, 2024 | $800.70M |
| Mar 31, 2024 | $0.53 | $0.46 | $0.45 - $0.49 | +15.22% | Beat | -17.2% | 10 | 0 up, 0 down | May 2, 2024 | $721.70M |
| Dec 31, 2023 | $0.70 | $0.66 | $0.62 - $0.89 | +6.06% | Beat | -5.4% | 11 | 3 up, 0 down | Feb 13, 2024 | $854.50M |
| Sep 30, 2023 | $0.74 | $0.63 | $0.62 - $0.65 | +17.46% | Beat | +12.1% | 9 | 1 up, 0 down | Nov 2, 2023 | $742.80M |
| Jun 30, 2023 | $0.50 | $0.49 | $0.46 - $0.50 | +2.04% | Beat | +11.1% | 10 | 0 up, 0 down | Aug 3, 2023 | $681.90M |
| Mar 31, 2023 | $0.64 | $0.55 | $0.53 - $0.59 | +16.36% | Beat | +30.6% | 10 | 0 up, 0 down | May 4, 2023 | $685.30M |
| Dec 31, 2022 | $0.74 | $0.72 | $0.69 - $0.75 | +2.78% | Beat | +25.4% | 10 | 4 up, 0 down | Feb 9, 2023 | $708.40M |
| Sep 30, 2022 | $0.66 | $0.56 | $0.52 - $0.71 | +17.86% | Beat | +4.8% | 10 | 0 up, 0 down | Nov 3, 2022 | $638.90M |
| Jun 30, 2022 | $0.45 | $0.45 | $0.44 - $0.46 | 0.00% | In line | +2.3% | 9 | 0 up, 0 down | Aug 3, 2022 | $588.40M |
| Mar 31, 2022 | $0.49 | $0.42 | $0.39 - $0.44 | +16.67% | Beat | +11.4% | 10 | 1 up, 0 down | May 4, 2022 | $595.00M |
| Dec 31, 2021 | $0.59 | $0.58 | $0.57 - $0.61 | +1.72% | Beat | +1.7% | 11 | 2 up, 0 down | Feb 11, 2022 | $683.50M |
| Sep 30, 2021 | $0.63 | $0.44 | $0.38 - $0.48 | +43.18% | Beat | +50.0% | 11 | N/A | Nov 1, 2021 | $608.90M |
| Jun 30, 2021 | $0.44 | $0.38 | $0.27 - $0.44 | +15.79% | Beat | +109.5% | 12 | N/A | Aug 2, 2021 | $570.80M |
| Mar 31, 2021 | $0.44 | $0.33 | $0.29 - $0.38 | +33.33% | Beat | +214.3% | 12 | N/A | May 5, 2021 | $554.70M |
| Dec 31, 2020 | $0.58 | $0.56 | $0.47 - $0.66 | +3.57% | Beat | +9.4% | 14 | N/A | Feb 16, 2021 | $627.50M |
| Sep 30, 2020 | $0.42 | $0.31 | $0.23 - $0.37 | +35.48% | Beat | -2.3% | 13 | N/A | Nov 2, 2020 | $511.40M |
| Jun 30, 2020 | $0.21 | $0.05 | $0.00 - $0.17 | +320.00% | Beat | -36.4% | 12 | N/A | Aug 3, 2020 | $424.60M |
| Mar 31, 2020 | $0.14 | $0.22 | $0.10 - $0.30 | -36.36% | Miss | -50.0% | 13 | N/A | May 6, 2020 | $424.00M |
| Dec 31, 2019 | $0.53 | $0.59 | $0.56 - $0.62 | -10.17% | Miss | -1.9% | 14 | N/A | Mar 27, 2020 | $1.66B |
| Sep 30, 2019 | $0.43 | $0.38 | $0.35 - $0.42 | +13.16% | Beat | +16.2% | 11 | N/A | Oct 31, 2019 | $1.04B |
| Jun 30, 2019 | $0.33 | $0.30 | $0.27 - $0.36 | +10.00% | Beat | +32.0% | 13 | N/A | Aug 1, 2019 | $980.40M |
| Mar 31, 2019 | $0.28 | $0.24 | $0.23 - $0.28 | +16.67% | Beat | +16.7% | 12 | N/A | May 2, 2019 | $461.40M |
| Dec 31, 2018 | $0.54 | $0.54 | $0.51 - $0.59 | 0.00% | In line | +5.9% | 13 | N/A | Feb 11, 2019 | $553.60M |
| Sep 30, 2018 | $0.37 | $0.30 | $0.28 - $0.31 | +23.33% | Beat | +27.6% | 13 | N/A | Nov 1, 2018 | $466.60M |
| Jun 30, 2018 | $0.25 | $0.25 | $0.18 - $0.29 | 0.00% | In line | +8.7% | 14 | N/A | Aug 2, 2018 | $443.70M |
| Mar 31, 2018 | $0.24 | $0.23 | $0.19 - $0.24 | +4.35% | Beat | +26.3% | 14 | N/A | May 3, 2018 | $431.70M |
| Dec 31, 2017 | $0.51 | $0.49 | $0.47 - $0.50 | +4.08% | Beat | +10.9% | 13 | N/A | Feb 8, 2018 | $530.50M |
| Sep 30, 2017 | $0.29 | $0.26 | $0.23 - $0.30 | +11.54% | Beat | -9.4% | 12 | N/A | Nov 2, 2017 | $435.60M |
| Jun 30, 2017 | $0.23 | $0.20 | $0.17 - $0.26 | +15.00% | Beat | +15.0% | 13 | N/A | Aug 3, 2017 | $414.90M |
| Mar 31, 2017 | $0.19 | $0.19 | N/A | 0.00% | In line | -9.5% | N/A | N/A | May 3, 2017 | $384.90M |
| Dec 31, 2016 | $0.46 | $0.36 | N/A | +27.78% | Beat | +21.1% | N/A | N/A | Feb 13, 2017 | $470.30M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $1.83, down 24.1% from the year before. It was $1.19 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $1.83 | -24.1% |
| Dec 31, 2024 | $2.41 | -6.6% |
| Dec 31, 2023 | $2.58 | +10.3% |
| Dec 31, 2022 | $2.34 | +11.4% |
| Dec 31, 2021 | $2.10 | +55.6% |
| Dec 31, 2020 | $1.35 | -14.0% |
| Dec 31, 2019 | $1.57 | +12.1% |
| Dec 31, 2018 | $1.40 | +14.8% |
| Dec 31, 2017 | $1.22 | N/A |
| Dec 31, 2016 | $1.19 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,300 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,259 | 14 | |
| 2026Q2 | Jun 30, 2026 | 7,195 | 13 | |
| 2026Q1 | Mar 31, 2026 | 6,480 | 12 | |
| 2025Q4 | Dec 31, 2025 | 7,515 | 12 | |
| 2025Q3 | Sep 30, 2025 | 3,743 | 12 | |
| 2025Q2 | Jun 30, 2025 | 7,329 | 14 | |
| 2025Q1 | Mar 31, 2025 | 5,937 | 9 | |
| 2024Q4 | Dec 31, 2024 | 7,160 | 14 |
2026Q3 Earnings Call
Opening remarks
Joe Kostka Director of Investor Relations Good morning. I would like to welcome everyone to Bruker Corporation's Third Quarter 2026 Earnings Conference Call. My name is Joe Kostka, and I am the Director of Bruker Investor Relations. Joining me on today's call are our President and CEO, Frank Laukien, and our EVP and CFO, Gerald Herman. In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events and Presentations section of Bruker's Investor Relations website. During today's call, we will be highlighting non-GAAP financial information. Reconciliations of our non-GAAP to GAAP financial measures are included in our earnings release and are posted on our website at ir.bruker.com. Before we begin, I would like to reference Bruker's safe harbor statement, which is shown on slide two of the presentation. During this conference call, we will or may make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to our recent acquisitions, geopolitical risks, wars or blockades, market demand, tariffs, currency exchange rates, competitive dynamics, or supply chains. The company's actual results may differ materially from such statements. Factors that might cause such differences include, but are not limited to, those discussed in today's earnings release and in our Form 10-K for the period ending December 31, 2025, as updated by our other SEC filings, which are available on our website and on the SEC's website. Also, please note that the following information is based on current business conditions and on our outlook as of today, November 4, 2026. We do not intend to update our forward-looking statements based on new information, future events, or for other reasons, except as may be required by law prior to the release of our fourth quarter and full year 2026 financial results, expected in February 2027. You should not rely on these forward-looking statements as necessarily representing our views or outlook as of any date after today. We will begin today's call with Frank Laukien providing an overview of our business progress. Gerald Herman will then cover the financials for the third quarter of 2026 in more detail and comment on our full year 2026 financial outlook. Now, I'd like to turn the call over to Bruker CEO, Frank Laukien.
Frank Laukien President and CEO Thank you, Joe Kostka. Good morning, everyone, and thank you for joining us on today's third quarter 2026 earnings call. Bruker continues to drive significant advances in post-genomic disease biology solutions and drug discovery, from proteoforms to glycobiology, and from functional protein interactions to spatial biology.
Frequently Asked Questions About BRKR
When is Bruker's next earnings date?
Bruker's next earnings report is expected for Feb 10, 2027.
Did BRKR beat earnings estimates last quarter?
Yes. Bruker reported EPS of $0.56 for the quarter ended Sep 30, 2026, above the $0.42 estimate, a 33.33% surprise.
What EPS do analysts expect from BRKR next quarter?
The consensus EPS estimate for Bruker for the quarter ending Dec 31, 2026 is $0.80 from 14 analysts, with estimates from $0.74 to $0.96.
How often does BRKR beat earnings estimates?
Bruker beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +14.27%.
BRKR pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts